Supotaria

• Chronic severe drooling: in patients aged 3-16 years with neurologic conditions (e.g., cerebral palsy)

Glycopyrrolate is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Glycopyrrolate indirectly reduces the rate of salivation by preventing the stimulation of these receptors. Glycopyrrolate inhibits the action of acetylcholine on salivary glands thereby reducing the extent of salivation.

Initial Dose:

• 0.02 mg/kg orally three times daily
• Titrate in increments of 0.02 mg/kg every 5-7 days
• Maximum: 0.1 mg/kg three times daily (not to exceed 1.5-3 mg per dose)

Administration:

• At least one hour before or two hours after meals
• Use accurate measuring device

* Use as directed by the registered physician

Common Side Effects:

• Abdominal distention
• Abdominal pain
• Chapped lips, dry tongue
• Constipation
• Headache
• Nasal congestion
• Dry skin
• Restlessness, agitation
• Upper respiratory tract infection
• Urinary tract infection

Use in Pregnancy: No adequate data in pregnant women. Use only if potential benefit justifies potential risk to the fetus.

Precautions:

• Constipation is a common dose-limiting reaction - monitor within 4-5 days of initial dosing or after dose increase
• Heat prostration can occur in high ambient temperatures - avoid exposure to hot environments
• May cause drowsiness or blurred vision - avoid driving or operating machinery

Overdose: Glycopyrrolate is a quaternary amine which does not easily cross the BBB - symptoms are peripheral. Maintain open airway, provide ventilation, manage hyperthermia, coma or seizures. Neostigmine may be administered.

Storage: Keep below 30°C, away from light and moisture. Keep out of reach of children.